Ardelyx (NASDAQ:ARDX) Shares Down 7.8% – Time to Sell?

Posted by Stanley Muller on Jun 29th, 2026

Ardelyx, Inc. (NASDAQ:ARDX – Get Free Report)’s share price dropped 7.8% during trading on Monday . The stock traded as low as $5.11 and last traded at $5.1150. 899,120 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 4,280,792 shares. The stock had previously closed at $5.55.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. Leerink Partners restated an “outperform” rating on shares of Ardelyx in a report on Thursday, March 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Ardelyx in a report on Monday, April 20th. LADENBURG THALM/SH SH assumed coverage on shares of Ardelyx in a research report on Tuesday, June 16th. They set a “buy” rating and a $16.00 target price on the stock. Finally, Williams Trading set a $17.00 target price on shares of Ardelyx in a report on Thursday, March 12th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $15.73.

Read Our Latest Stock Report on Ardelyx

Ardelyx Price Performance

The company has a fifty day moving average of $6.09 and a 200 day moving average of $6.30. The firm has a market capitalization of $1.32 billion, a P/E ratio of -23.19 and a beta of 0.58. The company has a debt-to-equity ratio of 1.37, a current ratio of 3.49 and a quick ratio of 3.28.

Ardelyx (NASDAQ:ARDX – Get Free Report) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.02). The firm had revenue of $94.47 million for the quarter, compared to analyst estimates of $92.78 million. Ardelyx had a negative net margin of 13.58% and a negative return on equity of 38.11%. The business’s revenue for the quarter was up 27.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.17) EPS. Sell-side analysts predict that Ardelyx, Inc. will post -0.07 earnings per share for the current year.

Insider Buying and Selling at Ardelyx

In other news, insider Mike Kelliher sold 7,248 shares of the stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.27, for a total transaction of $45,444.96. Following the completion of the sale, the insider directly owned 357,418 shares in the company, valued at $2,241,010.86. This represents a 1.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Eric Duane Foster sold 7,998 shares of Ardelyx stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.27, for a total transaction of $50,147.46. Following the transaction, the insider directly owned 417,972 shares of the company’s stock, valued at $2,620,684.44. This represents a 1.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 24,572 shares of company stock valued at $154,066. 5.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in ARDX. Mercer Global Advisors Inc. ADV lifted its stake in shares of Ardelyx by 4.7% in the 4th quarter. Mercer Global Advisors Inc. ADV now owns 38,512 shares of the biopharmaceutical company’s stock valued at $225,000 after purchasing an additional 1,722 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its holdings in Ardelyx by 26.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,807 shares of the biopharmaceutical company’s stock worth $69,000 after purchasing an additional 2,491 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Ardelyx by 0.7% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 347,609 shares of the biopharmaceutical company’s stock worth $2,027,000 after purchasing an additional 2,532 shares in the last quarter. Cerity Partners LLC lifted its stake in Ardelyx by 5.3% in the fourth quarter. Cerity Partners LLC now owns 59,359 shares of the biopharmaceutical company’s stock valued at $346,000 after buying an additional 2,972 shares during the period. Finally, Integrated Wealth Concepts LLC lifted its stake in Ardelyx by 24.2% in the third quarter. Integrated Wealth Concepts LLC now owns 15,263 shares of the biopharmaceutical company’s stock valued at $84,000 after buying an additional 2,975 shares during the period. 58.92% of the stock is owned by institutional investors.

About Ardelyx

(Get Free Report)

Ardelyx, Inc (NASDAQ: ARDX) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company’s lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx’s proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx’s development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.